Reduced albumin extravasation in experimental rat skin and muscle burn injury by D-myo-inositol-1,2,6-trisphosphate treatment.
This study investigated the effects of the anti-inflammatory agent D-myo-inositol-1,2,6-trisphosphate (IP3) on burn edema. Two sets of experiments were performed. In the first set, a full-thickness burn injury was induced in the abdominal skin of anesthetized rats. Postburn intravenous treatment was given with IP3, indomethacin or saline solution. Extravasation of Evans blue albumin in the burned tissue was quantified by a spectrophotometric technique. Results showed significant inhibition of albumin extravasation by IP3 in three of five different doses compared to saline-treated animals. In the second set of experiments, a deep full-thickness burn through the abdominal skin and rectus muscle was induced. The therapeutic window of IP3 could be more well-defined. Resulted showed a significant reduction of albumin extravasation in the skin at all four dose levels and in the abdominal muscle at three of four doses. Indomethacin had no significant effect on postburn edema formation. The mechanisms responsible for the inhibition of albumin leakage by IP3 could be secondary to reduced formation of edema-promoting inflammatory mediators by the agent, resulting in improved vascular patency.
Tarnow
P
P
Department of Plastic Surgery, Sahlgrenska University Hospital, Göteborg, Sweden.
Jönsson
A
A
Nellgård
P
P
Cassuto
J
J
D000418:Albumins / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002056:Burns / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D016001:Confidence Intervals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D005070:Evans Blue; D005119:Extravasation of Diagnostic and Therapeutic Materials; D007213:Indomethacin / Q000008:administration & dosage / Q000627:therapeutic use; D007295:Inositol Phosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D009132:Muscles / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012867:Skin / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D012965:Sodium Chloride / Q000008:administration & dosage / Q000627:therapeutic use
D000418:Albumins; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007295:Inositol Phosphates; D012965:Sodium Chloride; D005070:Evans Blue; C059368:atrinositol; D007213:Indomethacin